Compare Stocks: TRAW, DRCT, SLGL, and SCLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRCT Direct Digital	$0.54 -40.6%	$2.11	$0.45 ▼ $113.81	$730K	5.33	517,467 shs	177,747 shs
SCLX Scilex	$3.82 -5.9%	$5.63	$3.81 ▼ $27.00	$34.48M	1.72	31,420 shs	59,613 shs
SLGL Sol-Gel Technologies	$78.95 +9.7%	$73.94	$28.81 ▼ $97.97	$202.31M	1.14	45,305 shs	29,249 shs
TRAW Traws Pharma	$0.54 -5.7%	$0.54	$0.43 ▼ $3.27	$8.74M	1.52	1.57 million shs	161,351 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRCT Direct Digital	-40.65%	-64.47%	-72.44%	-80.07%	-99.23%
SCLX Scilex	-5.91%	-14.92%	-29.39%	-61.53%	-75.79%
SLGL Sol-Gel Technologies	+9.65%	+13.68%	+13.56%	+0.65%	+126.87%
TRAW Traws Pharma	-5.72%	-7.43%	-2.56%	-23.21%	-76.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRCT Direct Digital	$0.54 -40.6%	$2.11	$0.45 ▼ $113.81	$730K	5.33	517,467 shs	177,747 shs
SCLX Scilex	$3.82 -5.9%	$5.63	$3.81 ▼ $27.00	$34.48M	1.72	31,420 shs	59,613 shs
SLGL Sol-Gel Technologies	$78.95 +9.7%	$73.94	$28.81 ▼ $97.97	$202.31M	1.14	45,305 shs	29,249 shs
TRAW Traws Pharma	$0.54 -5.7%	$0.54	$0.43 ▼ $3.27	$8.74M	1.52	1.57 million shs	161,351 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRCT Direct Digital	-40.65%	-64.47%	-72.44%	-80.07%	-99.23%
SCLX Scilex	-5.91%	-14.92%	-29.39%	-61.53%	-75.79%
SLGL Sol-Gel Technologies	+9.65%	+13.68%	+13.56%	+0.65%	+126.87%
TRAW Traws Pharma	-5.72%	-7.43%	-2.56%	-23.21%	-76.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRCT Direct Digital	1.00	Sell	N/A	N/A
SCLX Scilex	1.00	Sell	N/A	N/A
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	150.16% Upside
TRAW Traws Pharma	1.80	Reduce	$1.00	86.57% Upside

Current Analyst Ratings Breakdown

Latest TRAW, DRCT, SLGL, and SCLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	DRCT Direct Digital	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/18/2026	SCLX Scilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	SCLX Scilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	TRAW Traws Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$1.00
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRCT Direct Digital	$34.69M	0.01	N/A	N/A	($18.82) per share	-0.03
SCLX Scilex	$30.25M	1.07	N/A	N/A	($24.94) per share	-0.15
SLGL Sol-Gel Technologies	$1.80M	123.59	N/A	N/A	$8.19 per share	9.64
TRAW Traws Pharma	N/A	N/A	$0.72 per share	0.74	($0.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRCT Direct Digital	-$18.95M	-$156.85	N/A	N/A	N/A	-74.38%	N/A	-68.48%	11/5/2026 (Estimated)
SCLX Scilex	-$358.73M	-$49.70	N/A	N/A	N/A	-1,414.57%	N/A	-147.00%	12/2/2026 (Estimated)
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	11/19/2026 (Estimated)
TRAW Traws Pharma	$9.17M	-$1.74	N/A	N/A	N/A	N/A	-23,868.92%	-165.52%	11/12/2026 (Estimated)

Latest TRAW, DRCT, SLGL, and SCLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/14/2026	Q2 2026	SCLX Scilex	-$0.1813	-$16.65	-$16.4687	-$16.65	$16.00 million	$7.64 million
8/14/2026	Q2 2026	TRAW Traws Pharma	-$0.3350	-$0.16	+$0.1750	-$0.16	N/A	N/A
8/12/2026	Q2 2026	DRCT Direct Digital	-$9.60	-$5.78	+$3.82	-$5.78	$8.84 million	$7.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRCT Direct Digital	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRCT Direct Digital	N/A	0.14	0.14
SCLX Scilex	N/A	0.07	0.06
SLGL Sol-Gel Technologies	N/A	10.37	10.37
TRAW Traws Pharma	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRCT Direct Digital	4.02%
SCLX Scilex	69.67%
SLGL Sol-Gel Technologies	26.18%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
DRCT Direct Digital	25.57%
SCLX Scilex	4.50%
SLGL Sol-Gel Technologies	66.51%
TRAW Traws Pharma	7.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRCT Direct Digital	73	800,000	598,000	Not Optionable
SCLX Scilex	34	8.49 million	8.11 million	No Data
SLGL Sol-Gel Technologies	28	2.81 million	941,000	No Data
TRAW Traws Pharma	7	15.37 million	14.21 million	No Data

TRAW, DRCT, SLGL, and SCLX Headlines

Recent News About These Companies

Head-To-Head Analysis: Traws Pharma (NASDAQ:TRAW) versus Jupiter Neurosciences (NASDAQ:JUNS)

October 4 at 4:44 AM | americanbankingnews.com

Traws Pharma shares rise after Q2 loss comes in better than expected

August 17, 2026 | finance.yahoo.com

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

August 14, 2026 | globenewswire.com

Traws Pharma Announces New At-The-Market Offering Program

July 10, 2026 | tipranks.com

Traws Pharma Stock Dividends | NASDAQ:TRAW | Benzinga

July 8, 2026 | benzinga.com

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

June 22, 2026 | globenewswire.com

Outlook for Bucks County biotech take another hit with second setback for flu drug

June 15, 2026 | bizjournals.com

Traws defers midphase flu study after negative regulatory review

June 15, 2026 | fiercebiotech.comF

Micron, Nebius surge premarket; Traws Pharma tumbles

June 15, 2026 | finance.yahoo.com

Traws Pharma shares slide after UK regulator postpones influenza study

June 15, 2026 | msn.com

Why did TRAW stock slump 28% after hours?

June 13, 2026 | msn.com

Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review

June 12, 2026 | quiverquant.comQ

Traws Pharma Provides Regulatory Update on Influenza Program

June 12, 2026 | globenewswire.com

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 27, 2026 | globenewswire.com

Traws Pharma Updates ATM Equity Offering Prospectus Supplements

May 26, 2026 | tipranks.com

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026 | globenewswire.com

Traws Pops on Hantavirus Research

May 9, 2026 | baystreet.ca

A hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gains

May 9, 2026 | msn.com

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

May 8, 2026 | benzinga.com

Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment

May 8, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, DRCT, SLGL, and SCLX Company Descriptions

Direct Digital NASDAQ:DRCT

$0.54 -0.37 (-40.65%)

As of 10/5/2026 03:59 PM Eastern

Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.

Scilex NASDAQ:SCLX

$3.82 -0.24 (-5.91%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$4.20 +0.38 (+9.95%)

As of 07:59 AM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Sol-Gel Technologies NASDAQ:SLGL

$78.95 +6.95 (+9.65%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$81.07 +2.12 (+2.69%)

As of 08:03 AM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Traws Pharma NASDAQ:TRAW

$0.54 -0.03 (-5.72%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$0.54 +0.01 (+1.31%)

As of 07:42 AM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRAW, DRCT, SLGL, and SCLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRAW, DRCT, SLGL, and SCLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRAW, DRCT, SLGL, and SCLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, DRCT, SLGL, and SCLX Company Descriptions

Direct Digital NASDAQ:DRCT

Scilex NASDAQ:SCLX

Sol-Gel Technologies NASDAQ:SLGL

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRAW, DRCT, SLGL, and SCLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRAW, DRCT, SLGL, and SCLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRAW, DRCT, SLGL, and SCLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, DRCT, SLGL, and SCLX Company Descriptions

Direct Digital NASDAQ:DRCT

Scilex NASDAQ:SCLX

Sol-Gel Technologies NASDAQ:SLGL

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools